1. T. Hijal MD, A. Al Hamad MD, N. Khalaf, K. Sultanem MD, S. Faria MD and T. Muanza MD McGill University, Department of Radiation Oncology, Montréal, Québec, Canada 2. Methods We conducted a retrospective review of the radiation oncology and hospital charts of the patients treated with a hypofractionated regimen of 42.4 Gy in 16 fractions of whole breast irradiation for a primary breast carcinoma or ductal carcinoma in situ (DCIS), at McGill University affiliated hospitals between March 2004 and January 2007. Clinical data was obtained from chart review. * The EORTC QLQ-C30 quality of life questionnaire as well the EORTC QLQ-BR23 breast cancer-specific quality of life questionnaire were either filled by the patients during their follow-up visits or mailed to them 1. Introduction Hypofractionated whole breast radiotherapy for early breast cancer has been widely adopted in Canada following the results of the Cancer Care Ontario breast fractionation schedule study. Nonetheless very few patients received chemotherapy in that study, and the toxicity of hypofractionated radiotherapy in patients receiving chemotherapy was not analysed. Furthermore the quality of life of these patients undergoing hypofractionated radiotherapy was not studied. We thus set to analyse the quality of life of patients undergoing hypofractionated radiotherapy, and to evaluate the impact of chemotherapy on its different components. 3. Whole population patient characteristics 6. Conclusion Baseline characteristics of the patients that responded to the questionnaire are similar to that of the overall group. Patients who underwent hypofractionated radiotherapy seem to enjoy a good quality of life after treatment, as measured by the EORTC QLQ-C30 and BR23 questionnaires. Furthermore, it appears that the addition of chemotherapy to hypofractionated whole breast irradiation has no adverse effect on the quality of life as measured by the aforementioned questionnaires.  Patient characteristics  EORTC QLQ-C30 quality of life and QLQ-BR23 breast cancer specific quality of life questionnaires administered Chemotherapy has no impact on quality of life when combined with a hypofractionated regimen of breast irradiation Number (%) Chemotherapy groupNo chemotherapy group Patients49113 Age at diagnosis median range 55 29-75 59 42-88 Follow-up median range 32 mo. 21-40 mo. 27 mo. 16-46 mo. T-stage Tis T1 T2 Tx 0 (0%) 33 (67%) 15 (31%) 1 (2%) 43 (38%) 57 (50%) 13 (12%) 0 (0%) N-stage N0 N1 Nx 33 (67%) 14 (29%) 2 (4%) 95 (84%) 3 (3%) 15 (13%) Additional boost given none 20 (41%) 29 (59%) 30 (27%) 83 (63%) Separation median range 19 cm 15-23.5 cm 19 cm 15-24 cm 4. Characteristics of questionnaire responders Retrospective chart review Breast cancer or DCIS Hypofractionated XRT 42.2 Gy in 16 Fx Adjuvant chemotherapy No chemotherapy 5. EORTC QLQ-C30 and BR23 scores Number (%) Chemotherapy groupNo chemotherapy group Patients2779 Age at diagnosis median range 59 29-72 60 40-87 Follow-up median 25 mo. T-stage Tis T1 T2 Tx 0 (0%) 22 (82%) 5 (18%) 0 (0%) 28 (35%) 41 (52%) 10 (13%) 0 (0%) N-stage N0 N1 Nx 18 (68%) 8 (29%) 1 (4%) 64 (81%) 0 (0%) 15 (19%) Additional boost given none 10 (37%) 17 (53%) 24 (30%) 55 (70%) Separation median19 cm Component (%) Chemotherapy group No chemotherapy group P-value Physical functioning 89.0789.210.95 Role functioning 91.3691.060.95 Dyspnea 17.2811.790.35 Pain 12.9613.370.92 Fatigue 21.7121.330.95 Appetite loss 11.114.940.16 Nausea and vomiting 7.410.820.12 Constipation 14.8111.250.55 Diarrhea 3.705.130.66 Cognitive 865.8086.320.88 Emotional 80.2578.850.77 Social 91.3694.440.43 Financial 13.587.020.27 QOL78.7073.160.28 Systemic therapy 17.6415.270.52 Hair loss 45.8321.740.22 Body image 82.1091.670.08 Future perspective 66.6767.110.95 Sexual function 78.6781.710.59 Sexual enjoyment 41.6754.320.33 Arm symptoms 13.999.400.27 Breast symptoms 15.7412.750.34